• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Leukemia risk models in primary myelofibrosis: an International Working Group study.

作者信息

Tefferi A, Pardanani A, Gangat N, Begna K H, Hanson C A, Van Dyke D L, Caramazza D, Vannucchi A M, Morra E, Cazzola M, Pereira A, Cervantes F, Passamonti F

出版信息

Leukemia. 2012 Jun;26(6):1439-41. doi: 10.1038/leu.2011.374. Epub 2012 Jan 13.

DOI:10.1038/leu.2011.374
PMID:22289985
Abstract
摘要

相似文献

1
Leukemia risk models in primary myelofibrosis: an International Working Group study.原发性骨髓纤维化的白血病风险模型：一项国际工作组研究。
Leukemia. 2012 Jun;26(6):1439-41. doi: 10.1038/leu.2011.374. Epub 2012 Jan 13.
2
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.C反应蛋白升高与骨髓纤维化患者无白血病生存期缩短有关。
Leukemia. 2013 Oct;27(10):2084-6. doi: 10.1038/leu.2013.207. Epub 2013 Jul 5.
3
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.DIPSS plus：一种改良的原发性骨髓纤维化动态国际预后评分系统，纳入了核型、血小板计数和输血状态的预后信息。
J Clin Oncol. 2011 Feb 1;29(4):392-7. doi: 10.1200/JCO.2010.32.2446. Epub 2010 Dec 13.
4
Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis.骨髓纤维化异基因造血干细胞移植的回顾性研究。
Bone Marrow Transplant. 2011 Apr;46(4):557-61. doi: 10.1038/bmt.2010.276. Epub 2010 Nov 1.
5
De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia.新发的der(1;7)(q10;p10)与原发性血小板增多症的白血病转化及不良预后相关。
Leuk Res. 2005 Nov;29(11):1247-52. doi: 10.1016/j.leukres.2005.03.011. Epub 2005 Apr 14.
6
Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients.原发性骨髓纤维化伴或不伴突变 MPL：603 例患者生存和临床特征的比较。
Leukemia. 2011 Dec;25(12):1834-9. doi: 10.1038/leu.2011.161. Epub 2011 Jun 21.
7
Improving survival trends in primary myelofibrosis: an international study.原发性骨髓纤维化的生存趋势改善：一项国际研究。
J Clin Oncol. 2012 Aug 20;30(24):2981-7. doi: 10.1200/JCO.2012.42.0240. Epub 2012 Jul 23.
8
Survival in young patients with intermediate- / high-risk myelofibrosis: estimates derived from databases for non transplant patients.中/高危骨髓纤维化年轻患者的生存情况：来自非移植患者数据库的估计值
Am J Hematol. 2009 Mar;84(3):140-3. doi: 10.1002/ajh.21342.
9
Risk factors for leukemic transformation in patients with primary myelofibrosis.原发性骨髓纤维化患者白血病转化的危险因素。
Cancer. 2008 Jun 15;112(12):2726-32. doi: 10.1002/cncr.23505.
10
Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival.年龄和血小板计数是原发性骨髓纤维化年轻患者中与 IPSS 无关的预后因素，补充 IPSS 可预测非常长或非常短的生存时间。
Eur J Haematol. 2010 Feb 1;84(2):105-8. doi: 10.1111/j.1600-0609.2009.01373.x. Epub 2009 Nov 6.

引用本文的文献

1
Myelofibrosis: Treatment Options After Ruxolitinib Failure.骨髓纤维化：芦可替尼治疗失败后的治疗选择
Curr Oncol. 2025 Jun 9;32(6):339. doi: 10.3390/curroncol32060339.
2
Real World Management of Cytopenias and Infections in Patients With Myelofibrosis Treated With Ruxolitinib.芦可替尼治疗的骨髓纤维化患者血细胞减少和感染的真实世界管理
EJHaem. 2025 Mar 21;6(2):e70007. doi: 10.1002/jha2.70007. eCollection 2025 Apr.
3
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.急变期骨髓增殖性肿瘤：当代综述与 2024 年治疗算法。
Blood Cancer J. 2023 Jul 18;13(1):108. doi: 10.1038/s41408-023-00878-8.
4
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis.血细胞减少表型在纤维化前期与明显原发性骨髓纤维化中的差异预后影响
Blood Cancer J. 2022 Aug 12;12(8):116. doi: 10.1038/s41408-022-00713-6.
5
Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.异基因造血干细胞移植治疗骨髓纤维化
Ther Adv Hematol. 2020 Feb 13;11:2040620720906002. doi: 10.1177/2040620720906002. eCollection 2020.
6
[Outcomes of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for 10 patients with myelofibrosis].[10例骨髓纤维化患者接受减低强度预处理异基因造血干细胞移植的结果]
Zhonghua Xue Ye Xue Za Zhi. 2018 Mar 14;39(3):225-230. doi: 10.3760/cma.j.issn.0253-2727.2018.03.010.
7
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.原发性和继发于特发性血小板增多症/原发性骨髓纤维化的血小板减少症患者的意义。
Eur J Haematol. 2018 Mar;100(3):257-263. doi: 10.1111/ejh.13005. Epub 2018 Jan 17.
8
[Advances in allogeneic hematopoietic stem cell transplantation for myelofibrosis].[骨髓纤维化异基因造血干细胞移植的进展]
Zhonghua Xue Ye Xue Za Zhi. 2017 Apr 14;38(4):352-356. doi: 10.3760/cma.j.issn.0253-2727.2017.04.020.
9
Myelofibrosis: to transplant or not to transplant?骨髓纤维化：移植还是不移植？
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):543-551. doi: 10.1182/asheducation-2016.1.543.
10
MYB deregulation from a EWSR1-MYB fusion at leukemic evolution of a JAK2 (V617F) positive primary myelofibrosis.在JAK2（V617F）阳性原发性骨髓纤维化白血病进展过程中，由EWSR1-MYB融合导致的MYB失调。
Mol Cytogenet. 2016 Sep 1;9(1):68. doi: 10.1186/s13039-016-0277-1. eCollection 2016.